2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-17464S2
    Cilostazol-d2 1073608-03-3 98%
    Cilostazol-d2 (OPC 13013-d2) is deuterium labeled Cilostazol. Cilostazol (OPC 13013) is a potent and selective inhibitor of phosphodiesterase (PDE) 3A, the isoform of PDE 3 in the cardiovascular system, with an IC50 of 0.2 μM.
    Cilostazol-d2
  • HY-17464S3
    Cilostazol-d6 1246641-05-3 98%
    Cilostazol-d6 (OPC 13013-d6) is deuterium labeled Cilostazol. Cilostazol (OPC 13013) is a potent and selective inhibitor of phosphodiesterase (PDE) 3A, the isoform of PDE 3 in the cardiovascular system, with an IC50 of 0.2 μM.
    Cilostazol-d6
  • HY-17494S1
    Timolol-d9 maleate 98%
    Timolol-d9 (maleate) is deuterium labeled Timolol. Timolol is a β-blocker available for both topical and systemic administration. Topical Timolol is primarily used to reduce intraocular pressure with open-angle glaucoma and ocular hypertension. Timolol can also be used for the research of infantile hemangiomas, hypertension, myocardial infarction, migraine prophylaxis, and atrial fibrillation.Timolol also has cardioprotective effect.
    Timolol-d9 maleate
  • HY-17497AR
    Acebutolol hydrochloride (Standard) 34381-68-5 98%
    Acebutolol (hydrochloride) (Standard) is the analytical standard of Acebutolol (hydrochloride). This product is intended for research and analytical applications. Acebutolol hydrochloride is an orally active β1 adrenergic receptor (β1AR) antagonist. Acebutolol hydrochloride is used in the treatment of hypertension, angina pectoris and cardiac arrhythmias.
    Acebutolol hydrochloride (Standard)
  • HY-17498S1
    Atenolol-d6 81346-72-7 98%
    Atenolol-d6 ((RS)-Atenolol-d6) is deuterium labeled Atenolol. Atenolol ((RS)-Atenolol) is a cardioselective β1-adrenergic receptor blocker, with a Ki of 697 nM at β1-adrenoceptor in guine pig left ventricle membrane. Atenolol can be used for the research of hypertension and angina pectoris.
    Atenolol-d6
  • HY-17498S3
    Atenolol-13C6 98%
    Atenolol-13C6 ((RS)-Atenolol-13C6) is 13C labeled Atenolol. Atenolol ((RS)-Atenolol) is a cardioselective β1-adrenergic receptor blocker, with a Ki of 697 nM at β1-adrenoceptor in guine pig left ventricle membrane. Atenolol can be used for the research of hypertension and angina pectoris.
    Atenolol-13C6
  • HY-17504BR
    Rosuvastatin Sodium (Standard) 147098-18-8 98%
    Rosuvastatin (Sodium) (Standard) is the analytical standard of Rosuvastatin (Sodium). This product is intended for research and analytical applications. Rosuvastatin Sodium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC50 of 11 nM. Rosuvastatin Sodium potently blocks hERG current with an IC50 of 195 nM. Rosuvastatin Sodium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Sodium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels.
    Rosuvastatin Sodium (Standard)
  • HY-17512AS
    Losartan-d6 hydrochloride 98%
    Losartan-d6 hydrochloride is deuterated labeled Losartan potassium (HY-17512A). Losartan potassium (DuP-753 potassium) is an angiotensin II receptor type 1 (AT1) antagonist, competing with the binding of angiotensin II to AT1 with an IC50 of 20 nM.
    Losartan-d6 hydrochloride
  • HY-179551S
    (±)11(12)-EET-d11 Methyl ester
    (±)11(12)-EET-d11 Methyl ester is the deuterium labeled (±)11(12)-EET methyl ester (HY-139938). (±)11(12)-EET methyl ester is a methylated derivative of 11,12-epoxyeicosatrienoic acid (11,12-EET) (HY-130494). (±)11(12)-EET methyl ester cannot induce β-arrestin recruitment of the G protein-coupled receptor GPR132. (±)11(12)-EET methyl ester fails to enhance the expression of hematopoietic stem and progenitor cell (HSPC) markers. (±)11(12)-EET methyl ester can be used as a negative control molecule to study the structure-function relationship of 11,12-EET, facilitating the analysis of the role of the oxygenated fatty acid-GPR132 signaling axis in hematopoiesis.
    (±)11(12)-EET-d11 Methyl ester
  • HY-18206AR
    Lisinopril dihydrate (Standard) 83915-83-7 98%
    Lisinopril (dihydrate) (Standard) is the analytical standard of Lisinopril (dihydrate). This product is intended for research and analytical applications. Lisinopri dihydrate (MK-521 dihydrate) is angiotensin-converting enzyme inhibitor, used in treatment of hypertension, congestive heart failure, and heart attacks.
    Lisinopril dihydrate (Standard)
  • HY-18206S1
    (S)-Lisinopril-d5 sodium 1356847-28-3 98%
    (S)-Lisinopril-d5 (sodium) (MK-521-d5 (sodium)) is deuterium labeled Lisinopril. Lisinopril (MK-521) is angiotensin-converting enzyme inhibitor, used in treatment of hypertension, congestive heart failure, and heart attacks.
    (S)-Lisinopril-d5 sodium
  • HY-18206S2
    Lisinopril-13C5,15N 98%
    Lisinopril-13C5,15N (MK-521-13C5,15N) is 13C and 15N labeled Lisinopril. Lisinopril (MK-521) is angiotensin-converting enzyme inhibitor, used in treatment of hypertension, congestive heart failure, and heart attacks.
    Lisinopril-13C5,15N
  • HY-18252S3
    Avanafil-13C5 98%
    Avanafil-13C5 (TA1790-13C5) is 13C labeled Avanafil. Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis.
    Avanafil-13C5
  • HY-18347AR
    Conivaptan hydrochloride (Standard) 168626-94-6 98%
    Conivaptan (hydrochloride) (Standard) is the analytical standard of Conivaptan (hydrochloride). This product is intended for research and analytical applications. Conivaptan (hydrochloride) is a non-peptide antagonist of vasopressin receptor, with Ki values of 0.48 and 3.04 nM for rat liver V1A receptor and rat kidney V2 receptor respectively.
    Conivaptan hydrochloride (Standard)
  • HY-18732AR
    L-NMMA acetate (Standard) 53308-83-1 98%
    L-NMMA (Tilarginine) acetate (Standard) is the analytical standard of L-NMMA acetate (HY-18732A). This product is intended for research and analytical applications. L-NMMA (Tilarginine) acetate is a non-selective and competitive inhibitor of nitric oxide synthase. L-NMMA acetate inhibits three subtypes, namely nNOS, eNOS, and iNOS, and reduces NO production. L-NMMA acetate alleviates mechanical allodynia, thermal hyperalgesia, and choroidal fibrosis. L-NMMA acetate is applicable to research related to nociception, bone cancer pain, and myopia.
    L-NMMA acetate (Standard)
  • HY-18734AR
    Carboxy-PTIO potassium (Standard) 148819-94-7
    Carboxy-PTIO (potassium) (Standard) is the analytical standard of Carboxy-PTIO (potassium). This product is intended for research and analytical applications. Carboxy-PTIO potassium is a potent nitric oxide (NO) scavenger that can make a quick reaction with NO to produce NO2. Carboxy-PTIO potassium can prevent hypotension and endotoxic shock through the direct scavenging action against NO in lipopolysaccharide-stimulated rat model.
    Carboxy-PTIO potassium (Standard)
  • HY-19638AR
    Cangrelor tetrasodium (Standard) 163706-36-3 98%
    Cangrelor (tetrasodium) (Standard) is the analytical standard of Cangrelor (tetrasodium). This product is intended for research and analytical applications. Cangrelor tetrasodium, an adenosine triphosphate analogue, is a reversible and selective platelet P2Y12 antagonist, with prompt and potent antiplatelet effects. Cangrelor tetrasodium directly blocks adenosine diphosphate (ADP)-induced activation and aggregation of platelets. Cangrelor tetrasodium is also a nonspecific GPR17 antagonist.
    Cangrelor tetrasodium (Standard)
  • HY-79593S3
    MRE-269-d7 sodium 2249828-87-1 98%
    MRE-269-d7 (ACT-333679-d7) sodium is deuterium-labeled MRE-269 (HY-79593).
    MRE-269-d7 sodium
  • HY-A0016S3
    Dronedarone-d6 1132693-87-8 98%
    Dronedarone-d6 (SR 33589-d6) is deuterium labeled Dronedarone. Dronedarone (SR 33589), a derivative of amiodarone (HY-14187), is a class III antiarrhythmic agent for the study of atrial fibrillation (AF) and atrial flutter. Dronedarone is a potent blocker of multiple ion currents, including potassium current, sodium current, and L-type calcium current, and exhibits antiadrenergic effects by noncompetitive binding to β-adrenergic receptors. Dronedarone is a substrate for and a moderate inhibitor of CYP3A4.
    Dronedarone-d6
  • HY-A0023AR
    Alogliptin (Standard) 850649-61-5 98%
    Alogliptin (Standard) is the analytical standard of Alogliptin. This product is intended for research and analytical applications. Alogliptin (SYR-322 free base) is a potent, selective and orally active inhibitor of DPP-4 with an IC50 of <10 nM, and exhibits greater than 10,000-fold selectivity over DPP-8 and DPP-9. Alogliptin can be used for the research of type 2 diabetes.
    Alogliptin (Standard)
Cat. No. Product Name / Synonyms Application Reactivity